Abdel-Magid, A.F. (2021). Cancer Immunotherapy through the Inhibition of Diacylglycerol Kinase Alpha and Zeta. ACS Med. Chem. Lett. 11, 1083-1085.
Abiko, K., Matsumura, N., Hamanishi, J., Horikawa, N., Murakami, R., Yamaguchi, K., Yoshioka, Y., Baba, T., Konishi, I., Mandai, M. (2015). IFN-γ from lymphocytes induces PD-L1 expression and promotes progression of ovarian cancer. British journal of cancer 112, 1501- 1509.
Arranz-Nicolás, J., Ogando, J., Soutar, D., Arcos-Pérez, R., Meraviglia-Crivelli, D., Mañes, S., Mérida, I., Ávila-Flores, A. (2018). Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals. Cancer Immunol. Immunother. 67, 965-980.
Arranz-Nicolás, J., Martin-Salgado, M., Adán-Barrientos, I., Liébana, R., Del., Carmen, Moreno-Ortíz, M., Leitner, J., Steinberger, P., Ávila-Flores, A., Merida, I. (2021). Diacylglycerol kinase α inhibition cooperates with PD-1-targeted therapies to restore the T cell activation program. Cancer. Immunol. Immunother. 70, 3277-3289.
Arranz-Nicolás, J., Martin-Salgado, M., Rodriguez-Rodriguez, C., Liébana, R., Moreno-Ortíz, M.C., Leitner, J., Steinberger, P., ÁvilaFlores, A., Merida, I. (2021). Diacylglycerol kinase zeta limits IL2-dependent control of PD-1 expression in tumor-infiltrating T lymphocytes. J. Immunother. Cancer 8, e001521.
Binnewies, M., Roberts, EW., Kersten, K., Chan, V., Fearon, DF., Merad, M., Coussens, LM., Gabrilovich, DI., Ostrand-Rosenberg, S., Hedrick, CC., et al. (2018). Understanding the tumor immune microenvironment (TIME) for effective therapy. Nat. Med. 24, 541- 550.
Cai, K., Mulatz, K., Ard, R., Nguyen, T., Gee, SH. (2014). Increased diacylglycerol kinase zeta expression in human metastatic colon cancer cells augments Rho GTPase activity and contributes to enhanced invasion. BMC Cancer 14, 208.
Calderaro, J., Rousseau, B., Amaddeo, G., Mercey, M., Charpy, C., Costentin, C., Luciani, A., Zafrani, ES., Laurent, A., Azoulay, D., Lafdil, F., Pawlotsky, JM. (2016). Programmed death ligand 1 expression in hepatocellular carcinoma: Relationship With clinical and pathological features. Hepatology (Baltimore, Md) 64, 2038-2046.
Cao, X., Cai, SF., Fehniger, TA., Song, J., Collins, LI., PiwnicaWorms, DR., Ley, TJ. (2007). Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 27, 635-646.
Cheng, AL., Hsu, C., Chan, SL., Choo, SP., Kudo, M. (2020). Challenges of combination therapy with immune checkpoint inhibitors for hepatocellular carcinoma. J. Hepatol. 72, 307-319.
Dai, X., Xue, J., Hu, J., Yang, SL., Chen, GG., Lai, PBS., Yu, C., Zeng, C., Fang, X., Pan, X., et al. (2017). Positive Expression of Programmed Death Ligand 1 in Peritumoral Liver Tissue is Associated with Poor Survival after Curative Resection of Hepatocellular Carcinoma. Translational oncology 10, 511-517.
Dojeu, JY., Jiang, K., Wei, S. (2002). A view of a kill: signals triggering cytoxicity. Clin. Cancer Res. 8, 636-640.
Dominguez, CL., Floyd, D.H., Xiao, A., Mullins, G.R., Kefas, B.A., Xin, W., Yacur, M.N., Abounader, R., Lee, J.K., Wilson, G.M., et al. (2013). Diacylglycerol kinase α is a critical signaling node and novel therapeutic target in glioblastoma and other cancers. Cancer Discov. 3, 782-797.
Eroglu, Z., Zaretsky, JM., Hu-Lieskovan, S., Kim, DW., Algazi, A., Johnson, DB., Liniker, E., Ben, K., Munhoz, R., Rapisuwon, S., et al. (2018). High response rate to PD-1 blockade in desmoplastic melanomas. Nature 553, 347-350.
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, DM., Forman, D., Bray, F. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136, E359-386.
Finn, RS., Qin, S., Ikeda, M., Galle, PR., Ducreux, M., Kim, TY., Kudo, M., Breder, V., Merle, P., Kaseb, AO., et al. (2020). Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma. N. Engl. J. Med. 382, 1894-1905.
Fu, L., Li, S., Xiao, W., Yu, K., Li, S., Yuan, S., Shen, J., Dong, X., Fang, Z., Zhang, J., et al. (2021). DGKA Mediates Resistance to PD-1 Blockade. Cancer Immunol. Res. 9, 371-385.
Goto, K., Hozumi, Y., Kondo, H. (2006). Diacylglycerol, phosphatidic acid, and the converting enzyme, diacylglycerol kinase, in the nucleus. Biochim. Biophys. Acta. 1761, 535-541.
Gu, J., Wang, C., Cao, C., Huang, J., Holizhauer, S., Desilva, H., Wesley, EM., Evans, D.B., Benci, J., Wichroski, M., et al (2021). Dgkζ ecerts greater control than DGKα over CD8+ T cell activity and tumor inhibition. Oncoimmunology, eCollection 2021.
Guo, R., Wan, CK., Carpenter, JH., Mousallem, T., Boustany, RM., Kuan, CT., Burks, AW., Zhong, XP. (2008). Synergistic control of T cell development and tumor suppression by diacylglycerol kinase alpha and zeta. Proc. Natl. Acad. Sci. U S A 105, 11909-11914.
Guo, Z., Jai, J., Yao, M., Kang, J., Wang, Y., Yan, X., Zhang, L., Lv, Q., Chen, X., Lu, F. (2018). Diacylglycerol kinase gamma predicts prognosis and functions as a tumor suppressor by negatively regulating glucose transporter 1 in hepatocellular carcinoma. Exp. Cell Res. 373, 211-220.
Hatanaka, T., Hiraoka, A., Tada, T., Hirooka, M., Kariyama, K., Tani, J., Atsukawa, M., Takaguchi, K., Itobayashi, E., fukunishi, S., et al. (2022). Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysis. Hepatol. Res. Online ahead of print.
Hui, E., Cheung, J., Zhu, J., Su, X., Taylor, MJ., Wallweber, HA., Sasmal, DK., Huang, J., Kim, JM., Mellman, I., Vale, RD. (2017). T cell costimulatory receptor CD28 is a primary target for PD-1- mediated inhibition. Science (New York, NY) 355, 1428-1433.
Jiang, W., Lu, Z., He, Y., Diasio, RB. (1997). Dihydropyrimidine dehydrogenase activity in hepatocellular carcinoma: implication in 5-fluorouracil-based chemotherapy. Clin. Cancer Res. 3, 395-399.
Jung, IY., Kim, YY., Yu, HS., Lee, M., Kim, S., Lee, J. (2018). CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells. Cancer Res. 78, 4692-4703.
Kai, M., Yamamoto, E., Sato, A., Yamano, HO., Kitajima, H., Harada, T., Aoki, H., Maruyama, R., Yoyota, M., Hatahira, T., et al. (2017). Epigenetic silencing of diacylglycerol kinase gamma in colorectal cancer. Mol. Carcinog. 56, 1743-1752.
Kanada, Y. (2013). Investigasion of the freely available easy-touse software ‘EZR’ for medical statictics. Bone Marrow Transplantat. 48, 452-458.
Kato, A., Miyazaki, M., Ambiru, S., Yoshitomi, H., Ito, H., Nakagawa, K., Shimizu, H., Yokosuka, O., Nakajima, N. (2001). Multidrug resistance gene (MDR-1) expression as a useful prognostic factor in patients with human hepatocellular carcinoma after surgical resection. J. Surg. Oncol. 78, 110-115.
Kefas, B., Floyd, D.H., Comeau L., Frisbee, A., Dominguez, C., Dipierro, C.G., Guessous, F., Abounader, R., Purow, B. (2013). A miR-297/hypoxia/DGK-alpha axis regulating glioblastoma survival. Neuro. Oncol. 15, 1652-1663.
Kim, JM., Chen, DS. (2016). Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure). Annals of oncology: official journal of the European Society for Medical Oncology 27, 1492-1504.
Kruger, S., Ilmer, M., Kobold, S., Cadilha, B., Endres, S., Ormanns, S., Schuebbe, G., Renz, B.W., D’Haese, J.G., Schloesser, H., et al. (2019). Advances in cancer immunotherapy 2019-Latest trends. J. Exp. Clin. Cancer Res. 38, 268.
Kudo, M., Izumi, N., Kubo, S., Kokudo, N., Sakamoto, M., Shiina, S., Tateishi, R., Nakashima, O., Murakami, T., Matsuyama, Y., et al. (2020). Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol. Res. 50, 15-46.
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, JJ., Cowey, CL., Lao, CD., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015). Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N. Engl. J. Med. 373, 23-34.
Liao, H., Chen, W., Dai, Y., Richardson, JJ., Guo, J., Yuan, K., Zeng, Y., Xie, K. (2019). Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. Frontiers in oncology 9, 883.
Liu, K., Kunii, N., Sakuma, M., Yamaki, A., Mizuno, S., Sato, M., Sakai, H., Kado, S., Kumagai, K., Kojima, H., et al. (2016). A novel diacylglycerol kinase α-selective inhibitor, CU-3, induces cancer cell apoptosis and enhances immune response. J. Lipid. Res. 57, 368- 379.
Liu, K., Xue, B., Bai, Z., Zhang, W. (2021). Downregulation of Diacylglycerol kinase zeta (DGKZ) surpresses tumorigenesis and progression of cervical cancer by facilitating cell apoptosis and cell cycle arrest. Bioengineered 1, 1517-1529.
Liu, Z., Zhao, Y., Fang, J., Cui, R., Xiao, Y., Xu, Q. (2017). SHP2 negatively regulates HLA-ABC and PD-L1 expression via STAT1 phosphorylation in prostate cancer cells. Oncotarget 8, 53518-53530.
Mandai, M., Hamanishi, J., Abiko, K., Matsumura, N., Baba, T., Konishi, I. (2016). Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity. Clin. Cancer Res. 22, 2329-2334.
Merida, I., Avila-Flores, A., Merino, E. (2008). Diacylglycerol kinase: At the hub of cell signaling. Biochem. J. 409, 1-18.
Merida, I., Andrada, E., Gharbi, S., Avila-Flores, A. (2015). Redundant and specialized roles for diacylglycerol kinase alpha and zeta in the control of T cell functions. Sci. Signal. 8, re6.
Mérida, I., Torres-Ayuso, P., Ávila-Flores, A., Arranz-Nicolás, J., Andrada, E., Tello-Lafoz, M., Liébana, R., Arcos, R. (2017). Diacylglycerol kinases in cancer. Adv. Biol. Regul. 63, 22-31.
Merida, I., Graziani, A., Sakane, F. (2017). Editorial: Diacylglycerol Kinase Signalling. Front. Cell Dev. Biol. 5, 84.
Nakano, T., Iravani, A., kim, M., Hozumi, Y., Lohse, M., Reichert, E., Crotty, TM., Stafforini, DM., Topham, MK. (2014). Diacylglycerol kinase eta modulates oncogenic properties of lung cancer cells. Clin. Trnsl. Oncol. 16, 26-35.
Noessner, E. (2017). DGK-α: A Checkpoint in Cancer-Mediated ImmunoInhibition and Target for Immunotherapy. Front. Cell. Dev. Biol. 5, 16.
Ohno, Y., Toyoshima, Y., Yurino, H., Monma, N., Xiang, H., Sumida, K., Kaneumi, S., Terada, S., Hashimoto, S., Ikeo, K., et al. (2017). Lack of interleukin-6 in the tumor microenvironment augments type-1 immunity and increases the efficacy of cancer immunotherapy. Cancer science 108, 1959-1966.
Olenchock, BA., Guo, R., Carpenter, JH., Jordan, M., Topham, MK., Koretzky, GA., Zhong, XP. (2006). Disruption of diacylglycerol metabolism impairs the induction of T cell anergy. Nat. Immunol. 7, 1174-1181.
Olmez, I., Love, S., Xiao, A., Manigat, L., Randolph, P., McKenna, BD., Neal, BP., Boroda, S., Li, M., Brenneman, B., et al. (2018). Targeting the mesenchymal subtype in glioblastoma and other cancers via inhibition of diacylglycerol kinase alpha. Neuro. Oncol. 20, 192-202.
Printz, P.U., Mendler, A.N., Masouris, I., Durret, L., Oberneder, R., Noessner, E. (2012). High DGK-alpha and disabled MAPK pathways cause dysfunction of human tumor-infiltrating CD8+ T cells that is reversible by pharmacologic intervention. J. Immunol. 188, 5990-6000.
Quail, DF., Joyce, JA. (2013). Microenvironmental regulation of tumor progression and metastasis. Nat. Med. 19, 1423-1437.
Rainero, E., Cianflone, C., Proporato, P.E., Chianale, F., Malacarne, V., Bettio, V., Ruffo, E., Ferrara, M., Benecchia, F., Capello, D., et al. (2014). The diacylglycerol kinase aipha/atypical PKC/beta1 integrin pathway in SDF-1 alpha mammary carcinoma invasiveness. Plos ONE 9, e97144.
Riese, MJ., Wang, LC., Moon, EK., Joshi, RP., Ranganathan, A., June, CH., Koretzky, GA., Albelda, SM. (2013). Enhanced effector responses in activated CD8+ T cells deficient in diacylglycerol kinases. Cancer Res. 73, 3566-3577.
Riese, MJ., Moon, EK., Johnson, BD., Albelda, SM. (2016). Diacylglycerol Kinases (DGKs): Novel Targets for Improving T Cell Activity in Cancer. Front. Cell Dev. Biol. 4, 108.
Sakane, F., Yamada, K., Kanoh, H., Yokoyama, C., Tanabe, T. (1990). Porcine diacylglycerol kinase sequence has zinc finger and E-F hand motifs. Nature 344, 345-348.
Sakane, F., Mizuno, S., Komenoi, S. (2016). Diacylglycerol Kinases as Emerging Potential Drug Targets for a Variety of Diseases: An Update. Front. Cell Dev. Biol. 4, 82.
Sakane, F., Hoshino, F., Ebina, M., Sakai, H., Takahashi, D. (2021). The Roles of Diacylglycerol Kinase α in Cancer Cell Proliferation and Apoptosis.
Sharma, P., Allison, JP. (2015). The future of immune checkpoint therapy. Science (New York, NY) 348, 56-61.
Shulga, YV., Topham, MK., Epand, RM. (2011). Regulation and functions of diacylglycerol kinases. Chemical reviews 111, 6186-6208.
Sun, C., Mezzadra, R., Schumacher, TN. (2018). Regulation and Function of the PD-L1 Checkpoint. Immunity 48, 434-452.
Takao, S., Akiyama, R., Sakane, F. (2020). Combined inhibition/silencing of diacylglycerol kinase alpha and zeta simultaneously and synergistically enhances interleukin-2 production in T cells and induces cell death of melanoma cells. J. Cell Biochem. 122, 494-506.
Takeishi, K., Taketomi, A., Shirabe, K., Toshima, T., Motomura, T., Ikegami, T., Yoshizumi, T., Sakane, F., Maehara, Y. (2012). Diacylglycerol kinase alpha enhances hepatocellular carcinoma progression by activation of Ras-Raf-MEK-ERK pathway. J. Hepatol. 57, 77-83.
Topalian, SL., Drake, CG., Pardoll, DM. (2015). Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27, 450-461.
Topham, M.K., Epand, R.M., (2009). Mammalian diacylglycerol kinase: Molecular interactions and biological functions of selected isoforms. Biochim. Biophys. Acta. 1790, 416-424.
Torres-Ayuso, P., Daza-Martin, M., Martin-Perez, J. Avila-Flores, A., Merida, I. (2014). Diacylglycerol kinase α promotes 3D cancer cell growth and limits drug sensitivity through functional interaction with Src. Oncotarget 5, 9710-9726.
Tumeh, PC., Harview, CL., Yearley, JH., Shintaku, IP., Taylor, EJ., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., West, AN., et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515, 568-571.
Wu, K., Kryczek, I., Chen, L., Zou, W., Welling, TH. (2009). Kupffer cell suppression of CD8+ T cells in human hepatocellular carcinoma is mediated by B7-H1/programmed death-1 interactions. Cancer. Res. 69, 8067-8075.
Yamada, K., Sakane, F., Kanoh, H. (1989). Immunoquantitation of 80kDa diacylglycerol kinase in pig and human lymphocytes and several other cells. FEBS Lett. 244, 402-406.
Yamaki, A., Akiyama, R., Murakami, C., Takao, S., Murakami, Y., Mizuno, S., Takahashi, D., Kado, S., Taketomi, A., Shirai, Y., et al. (2019). Diacylglycerol kinase α-selective inhibitors induce apoptosis and reduce viability of melanoma and several other cancer cell lines. J. Cell Biochem. 120, 10043-10056.
Yanagisawa, K., Yasuda, S., Kai, M., Imai, S., Yamada, K., Yamashita, T., Jimbow, K., Kanoh, H., Sakane, F. (2007). Diacylglycerol kinase alpha suppresses tumor necrosis factor-alpha-induced apoptosis of human melanoma cells through NF-kappaB activation. Biochim. Biophys. Acta. 1771, 462-474.
Yao, W., He, JC., Yang, Y., Wang, JM., Qian, YW., Yang, T., Ji, L. (2017). The Prognostic Value of Tumor-infiltrating Lymphocytes in Hepatocellular Carcinoma: a Systematic Review and Meta-analysis. Scientific reports 7, 7525.
Yokosuka, T., Takamatsu, M., Kobayashi-Imanishi, W., Hashimoto-Tane, A., Azuma, M., Saito, T. (2012). Programmed cell death 1 forms negative costimulatory microclusters that directly inhibit T cell receptor signaling by recruiting phosphatase SHP2. The Journal of experimental medicine 209, 1201-1217.
Zha, Y., Marks, R., Ho, A.W., Peterson, A.C., Janardhan, S., Brown, I., Praveen, K., Stang, S., Stone, J.C., Gajewski, T.F. (2006). T cell anergy is reversed by active Ras and is regulated by diacylglycerol kinase-α. Nat. Immunol. 7, 1166-1173.
Zhao, Y., Sun H., Li, X., Liu, Y., Jin, W. (2022). DGKZ promotes TGFβ signaling pathway and metastasis in triple-negative breast cancer by suppressing lipid raft-dependent endocytosis of TGFβR2. Cell Death Dis. 13, 105.
Zhou, P., Shaffer, D.R., Alvarez Arias, D.A., Nakazaki, Y., Pos, W., Torres, A.J., Cremasco, V., Dougan, S., Cowley, G.S., Elpek, K., et al. (2014). In vivo discovery of immunotherapy targets in the tumor microenvironment. Nature 506, 52-57.
Zou, W., Wolchok, JD., Chen, L. (2016). PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations. Science translational medicine 8, 328rv324.